UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September 19, 2007
Opexa Therapeutics, Inc.
------------------------
(Exact Name of Registrant as Specified in Its Charter)
Texas
-----
(State or Other Jurisdiction of Incorporation)
001-33004 76-0333165
--------- ----------
(Commission File Number) (I.R.S. Employer
Identification No.)
2635 N. Crescent Ridge Drive
The Woodlands, Texas 77381
-------------------- -----
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (281) 272-9331
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 19, 2007, the board of directors appointed Lorin Jeffry (Jeff)
Randall to the Board of Directors. Mr. Randall was also appointed to the board's
audit committee replacing Dr. David Hung, who resigned from the audit committee,
but remains a member of the board of directors.
From 2004 to 2006, Mr. Randall was senior vice president - chief financial
officer of Eximias Pharmaceutical Corporation, a development stage provider of
oncology therapeutics. From 2002-2004, Mr. Randall held the same position at
i-STAT Corporation, a manufacturer of medical diagnostic devices, which was
acquired by Abbott Laboratories in 2004. His career also included senior
management positions at CFM Technologies, a semiconductor manufacturing
equipment company; Greenwich Pharmaceutical Corporation, a development stage
provider of immune system disease therapeutics; and Surgilase, a provider of
surgical lasers to hospitals and clinics. Mr. Randall received a B.S. in
accounting from The Pennsylvania State University and an M.B.A. from
Northeastern University.
Mr. Randall has not been involved with a related transaction or relationship as
defined by Item 404(a) of Regulation S-B with the Company.
A copy of the press release is attached as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
(c) Exhibit 99.1
The following exhibit is to be filed as part of this 8-K:
Exhibit No. Description
- ----------- -----------
99.1 Press release issued September 20, 2007
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
OPEXA THERAPEUTICS, INC.
By: /s/ David B. McWilliams
---------------------------------------------
David B. McWilliams, Chief Executive Officer
DATE: September 19, 2007
EXHIBIT INDEX
Exhibit No. Description
- ----------- -----------
99.1 Press release issued September 20, 2007